| Autor: |
Grossman, J., Banov, C., Boggs, P., Bronsky, E.A., Dockhorn, R.J., Druce, H., Findlay, S.R., Georgitis, J.W., Hampel, F.C., Kaiser, H., Ratner, P., Tinkelman, D.G., Valentine, M.D., Roszko, P., Zegarelli, E., Wood, C. |
| Zdroj: |
The Journal of Allergy and Clinical Immunology; May 1995, Vol. 95 Issue: 5 p1123-1127, 5p |
| Abstrakt: |
To study the long-term safety and effectiveness of ipratropium bromide nasal spray 0.03% in the treatment of nonallergic perennial rhinitis, we administered this medication for 1 year in an open-label trial involving 285 patients. Our intention was to maintain the highest protocol dose possible to gain a clearer picture of the long-term side effect profile of the compound. Ipratropium bromide was well tolerated with no serious side effects in this patient population. It provided a significant improvement in rhinorrhea throughout the year-long trial; only 17 of 285 patients (6%) were considered treatment failures. There was an improvement in patient quality of life, as well as a substantial reduction in the need for other medications (antihistamines, decongestants, and nasal steroids) used to treat perennial rhinitis symptoms. (J ALLERGY CLIN IMMUNOL 1995;95:1123-7.) |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full Text from ScienceDirect